Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
about
DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaquesHeterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinStructural allele-specific patterns adopted by epitopes in the MHC-I cleft and reconstruction of MHC:peptide complexes to cross-reactivity assessmentObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesRepeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitHIV neutralizing antibodies: clinical correlates and implications for vaccines.Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routesDNA vaccines: developing new strategies against cancer.Rational antibody-based HIV-1 vaccine design: current approaches and future directionsGlycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.The influence of delivery vectors on HIV vaccine efficacyLong-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremiaOral and nasal DNA vaccines delivered by attenuated Salmonella enterica serovar Typhimurium induce a protective immune response against infectious bronchitis in chickens.Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.HIV DNA Vaccine: Stepwise Improvements Make a Difference.DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administrationRhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationThe safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteersFrequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.Polyvalent AIDS vaccines.Viral sequence diversity: challenges for AIDS vaccine designs.Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.HIV/AIDS vaccines: a need for new concepts?Heterologous prime-boost vaccination.Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.Therapeutic and prophylactic DNA vaccines for HIV-1.Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.Identification of Aim2 as a sensor for DNA vaccines.
P2860
Q27316075-3ECE1BA0-F376-41B1-B457-C4E307411B5DQ28394899-45F50F5D-C100-4457-9E7F-3D03BB9707C0Q28743092-CB656143-DF7B-437C-9FA2-05A41F5EFE07Q28752409-78E13EC7-094F-4BF5-BED7-6335621E00B3Q30378897-7106C9A7-7AE8-4666-861C-735C84A19AA9Q30379200-85B38DE7-26A7-4AE0-A2DE-DE2A25694494Q31138173-2E35FBE2-18D7-4868-BDF7-A0E77CAD861EQ33614495-B9F0A881-F0AC-403D-8DC0-F0E6E7E3728BQ33698152-D6B344CA-2708-409F-846E-1947485721F5Q33703451-C867C68F-1714-4315-B9B6-E669595332C4Q33743758-4FE85B8F-7A3B-49E2-980E-8CECDC1E19E5Q33756622-0C2DE9E0-C0E8-4C7F-ABF9-863868D335FFQ33937285-C23035B4-9998-4249-A923-6BD2A3C3133EQ33967039-A3A64806-66ED-4575-B5F2-6B94BA5223C5Q34077543-DDD99E50-AFE1-44FA-BD9A-C7A2996DCC9AQ34099837-72C04BCA-17DB-4C6E-B2E6-F42BFB1CF9F0Q35060140-6DD4813A-E886-4FD8-BA0C-34DDF2CD1F83Q35076664-0E3D0BE0-38C8-49BE-98B5-C927DEDE3339Q35077039-F72BABA0-C22F-4702-A47F-6ED5461AB502Q35138696-2B1F3D65-D718-46FE-97CA-4ECC84B04A0EQ35478282-BD62AF44-3C94-4F37-847B-C2ED7BFBB227Q35826742-1E566C83-2BCF-4F92-A0C5-EFBC846EFF65Q36694841-AC442A3C-F0ED-43C1-A9CB-A03A2F646AE1Q36748019-B6EC0B83-908D-427D-B702-1101AA518DECQ36798324-36FE8C8E-88D7-475B-8259-A27BAE458EE0Q36804634-4EE120C5-F239-4542-B0F4-D298D5968C0FQ36945335-BB3ACDC6-2B97-4779-8314-EE7CC6AC67EFQ37033269-B04EE97E-2F36-4A97-9080-4B938B597721Q37033291-71E1D47F-D176-4652-B5FF-07A7A51F7C10Q37094429-330DDA00-B8EE-4783-8B13-36FAA17F3DF3Q37316023-5265A2C3-2E0F-4FB8-85C8-FDF80FC59CABQ37336704-2D1B915B-EEEE-477C-B549-5DBDB17F8CF7Q37344236-D286C259-8D64-4E1A-B9BD-96B0C46E4FCBQ37509586-115F3A3E-9426-4F1F-B7CB-9F5D383B54CBQ37668114-15383E6F-A2BB-4208-A323-2ED70CE539ABQ38088037-86B4FE66-2EF8-4FC5-9445-5EE2690BB9DBQ38184579-30FE5255-A490-4EC7-82A8-2BAE61E35C2AQ38356290-A203E429-6142-44DC-A4B9-A1DC1E9678D6Q41222915-1E41737D-8C9F-4C96-B372-100F9DEFACA1Q41609361-C83DDD0C-4A5E-41D7-AB55-C5130FA41577
P2860
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@ast
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@en
type
label
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@ast
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@en
prefLabel
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@ast
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@en
P2093
P2860
P1433
P1476
Cross-subtype antibody and cel ...... ne in healthy human volunteers
@en
P2093
Alan L Rothman
Francis A Ennis
James Arthos
Jeffrey S Kennedy
John Lawrence
Phillip Markham
Ranajit Pal
Scott Coley
P2860
P304
P356
10.1016/J.VACCINE.2007.12.024
P407
P577
2008-01-10T00:00:00Z